TRx-237-015 Clinical Study

 This clinical trial will assess the safety and efficacy of LMTX™ in up to 833 patients diagnosed with mild to moderate Alzheimer’s.  The main measures of efficacy to be used in the study are:

  1. The change in study subjects’ performance at the beginning and the end of the study in two commonly used clinical assessments:

a.  The Alzheimer’s Disease Assessment Scale – Cognitive Subscale, known as ADAS-cog11

b. The Modified Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change, known as ADCS-CGIC

2. The safety and tolerability of LMTX™ given for up to 18 months

The treatment period will be 15 months and the study, which will be placebo-controlled, is planned to take place at over 100 clinical sites primarily in North America, the EU, Russia, Australia and Southeast Asia and it is planned to last for 2½ years.


Global Alzheimer's study site locator

If you are a patient, caregiver, or family member of someone with Alzheimer's and interested in learning more, click the link below to find a clinical research study site near you. (Please note that this information is managed by a third-party, MediciGlobal.) 

FTD Global Study Locator

Alzheimer's Global Study Locator

Genting Invests with TauRx for Stake in Alzheimer's Market Leadership